Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...
Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...
Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...
American biotech Third Harmonic Bio and Inventiva have announced plans to reduce their respective workforces by 50% as part of cost-cutting measures. Both companies are shifting their focus to a ...